Lilly Reports Lung-Cancer Responses as Olomorasib Heads Toward Phase 3 Readout - FINCHANNEL

Eli Lilly reports promising lung cancer drug results (LLY:NYSE)

Lilly’s olomorasib showed promising lung cancer trial results, boosting its KRAS G12C treatment outlook ahead of key Phase 3 data.

Lilly reports lung-cancer responses as olomorasib heads toward Phase 3 readout - FINCHANNEL

Lilly reports lung-cancer responses as olomorasib heads toward Phase 3 readout

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels

Eli Lilly’s Olomorasib Posts a 62% Response Rate in Lung Cancer Study

The 77-patient combination group had median progression-free survival of 11.6 months. First randomized Phase 3 data are expected in the first half of 2027.

Lilly reports olomorasib lung-cancer response durability

Lilly reports a 62% response rate with an olomorasib lung-cancer combination. Randomized SUNRAY-01 results are expected in the first half of 2027.